Preclinical Drug Discovery: Turning Drug Safety Data into Decisions, Upcoming Webinar Hosted by Xtalks

In this free webinar, learn how the value of preclinical data lies in how it is curated, interpreted and applied in decision-making. Attendees will gain insight into why transparency, interpretability and reproducibility are essential for predictive technologies to be accepted and trusted. The featured speakers will share ways data-driven technologies can effectively integrate with regulatory workflows such as ICH S1B, ICH M7 and emerging frameworks such as ICH Q3E. The speakers will also discuss how these data-driven technologies support toxicity profiling, lead compound selection and evaluation of preclinical predictivity for clinical outcomes.

TORONTO, Oct. 2, 2025 /PRNewswire/ — In the current drug development landscape, data serves as the engine that drives faster and more strategic decisions. Despite the availability of data in preclinical research, organizations continue to face challenges in transforming data into meaningful insights that influence business outcomes. Additionally, regulatory expectations require transparency and interpretability of predicted outputs, which increases the need for standardization of quality data and overall governance of predictive technologies.

To address these challenges, organizations can strategically leverage data by first ensuring consistency and reliability, which underpins predictive technologies. Such curated data supports predictive modeling that complies with regulatory standards and allows systematic processing of millions of records. For instance, it helps identify potential adverse effects when modulating a drug target and semantic mapping of ontologies and concepts to maximize the use of standardized nonclinical data and bridge preclinical and clinical insights. Such strategic use of data enables organizations to shift towards a proactive decision-making framework, where insights are traceable and delivered efficiently.

To explore how these challenges are being addressed in practice, this webinar will showcase technologies designed to maximize data value across the preclinical research lifecycle. This webinar will highlight critical technology capabilities, such as integration into workflows supporting regulatory guidelines like ICH S1B (potentially replacing the two-year rat carcinogenicity study), ICH M7 and the emerging concepts in Step 2 of the ICH Q3E guideline currently under public consultation. Finally, this webinar will explore non-regulatory applications, such as an evaluation of drug candidate toxicity profiling and evaluating the predictivity of preclinical studies for clinical outcomes.

Register for this webinar to learn how data-driven strategies can enhance preclinical drug discovery and improve downstream decision-making.

Join experts from Instem for the live webinar on Thursday, October 16, 2025, at 10am EDT (4pm CEST/EU-Central). The session will feature speakers Frances Hall, PhD, Scientific Application Director; and Candice Johnson, PhD, Product Manager; along with Q&A Panelists Brenda Finney, PhD, Director of Product – In Silico & Data Insights; and Kevin Cross, PhD, Director of In Silico Science.

For more information or to register for this event, visit Preclinical Drug Discovery: Turning Drug Safety Data into Decisions.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit www.xtalks.com
For information about hosting a webinar, visit www.xtalks.com/why-host-a-webinar/

Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: vkovacevic@xtalks.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/preclinical-drug-discovery-turning-drug-safety-data-into-decisions-upcoming-webinar-hosted-by-xtalks-302573380.html

SOURCE Xtalks